- Raw materials
- Antibacterials
- Procalcitonin
Procalcitonin API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Procalcitonin | CAS No: 56645-65-9 | GMP-certified suppliers
A medication that serves as a peptide precursor investigated for guiding antibiotic therapy in severe COPD exacerbations and infection-related clinical decision-making.
Therapeutic categories
Product Snapshot
- Procalcitonin is an investigational peptide biomarker assay used in diagnostic applications
- It is primarily utilized to support the identification of bacterial infections and sepsis
- The product is currently in investigational status and has not received approval from key regulatory agencies such as the FDA or EMA
Clinical Overview
The mechanistic and pharmacodynamic profiles of procalcitonin remain incompletely characterized in the public domain. Procalcitonin is produced in response to systemic bacterial infections and inflammation, which underpins its utility as a biomarker in clinical settings rather than a direct pharmacological agent. It serves as a protein precursor to calcitonin, which is involved in calcium homeostasis and bone metabolism, although procalcitonin itself does not appear to have a direct hormonal action.
Pharmacokinetic data specific to exogenously administered procalcitonin are limited, with endogenous levels typically measured in plasma to assess infection severity. The absorption, distribution, metabolism, and excretion (ADME) characteristics related to pharmaceutical formulations of procalcitonin require further elucidation through clinical research.
Safety and toxicity profiles remain under investigation; no conclusive data are currently available. As a non-approved substance, procalcitonin is primarily utilized as a biomarker rather than as a therapeutic API. There are no marketed pharmaceutical brands or products based on procalcitonin as an active pharmaceutical ingredient.
For sourcing and quality assurance, procalcitonin APIs intended for research or diagnostic applications should be procured from manufacturers adhering to stringent quality control standards, including compliance with Good Manufacturing Practice (GMP) and relevant pharmacopeial guidelines. Analytical verification of purity, identity, and biological activity is critical due to its peptide nature and sensitivity to degradation.
Identification & chemistry
| Generic name | Procalcitonin |
|---|---|
| Molecule type | Biotech |
| CAS | 56645-65-9 |
| UNII | SV1QL0ZSJ9 |
| DrugBank ID | DB14812 |
Formulation & handling
- Procalcitonin is a biotech-derived peptide typically requiring parenteral (injectable) administration due to its protein nature.
- Formulation must consider proteolytic stability and protection from enzymatic degradation during storage and delivery.
- Storage conditions should minimize exposure to temperature fluctuations and light to preserve molecular integrity.
Regulatory status
Procalcitonin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
